Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) – Pipeline Review, H2 2017’, provides in depth analysis on Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Ophthalmology, Cardiovascular, Oncology, Dermatology, Immunology, Infectious Disease and Respiratory under development targeting Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)

The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Avipero Ltd

Clanotech AB

Morphic Therapeutic Inc

Strykagen Corp

Valeant Pharmaceuticals International Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Overview 7

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Companies Involved in Therapeutics Development 21

Avipero Ltd 21

Clanotech AB 21

Morphic Therapeutic Inc 21

Strykagen Corp 22

Valeant Pharmaceuticals International Inc 22

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Drug Profiles 24

Antibody + Small Molecule - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

AXT-108 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

C-16Y - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CLT-28643 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Recombinant Protein to Antagonize ITGA3 and ITGB1 for Oncology - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

SAL-021 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Stryka-232 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Stryka-234 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Stryka-425 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Stryka-516 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Stryka-516s - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Stryka-533 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Stryka-969 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Stryka-978 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

StrykaPro-1 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Synthetic Peptides to Antagonize Alpha5Beta1 Integrin for Breast and Prostate Cancer - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Dormant Products 44

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Discontinued Products 48

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Product Development Milestones 49

Featured News & Press Releases 49

Jun 15, 2015: Clanotech's lead compound in development, CLT-28643, has recently been granted a European Patent by the European Patent Office 49

May 12, 2015: Clanotech to present CLT-28643 in the treatment of eye disease at BioTrinity 2015 on 13 May 2015 49

Mar 27, 2015: Clanotech granted Orphan Drug Designation by the U.S. FDA 50

Oct 20, 2014: Clanotech receives orphan drug designation in the EU 50

Dec 23, 2013: Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis 50

Oct 25, 2013: Santarus Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting 51

Mar 10, 2011: Santarus Initiates Phase I Clinical Study With SAN-300 51

Appendix 53

Methodology 53

Coverage 53

Secondary Research 53

Primary Research 53

Expert Panel Validation 53

Contact Us 53

Disclaimer 54

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Products under Development by Companies, H2 2017 12

Number of Products under Investigation by Universities/Institutes, H2 2017 13

Products under Investigation by Universities/Institutes, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Pipeline by Avipero Ltd, H2 2017 21

Pipeline by Clanotech AB, H2 2017 21

Pipeline by Morphic Therapeutic Inc, H2 2017 22

Pipeline by Strykagen Corp, H2 2017 22

Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 23

Dormant Products, H2 2017 44

Dormant Products, H2 2017 (Contd..1), H2 2017 45

Dormant Products, H2 2017 (Contd..2), H2 2017 47

Discontinued Products, H2 2017 48

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports